187 related articles for article (PubMed ID: 35965290)
1. Janus kinase (JAK) inhibitors significantly reduce the humoral vaccination response against SARS-CoV-2 in patients with rheumatoid arthritis.
Schäfer A; Kovacs MS; Eder A; Nigg A; Feuchtenberger M
Clin Rheumatol; 2022 Dec; 41(12):3707-3714. PubMed ID: 35965290
[TBL] [Abstract][Full Text] [Related]
2. Methotrexate significantly reduces the humoral vaccination response against SARS-CoV-2 in older but not younger patients with rheumatoid arthritis.
Feuchtenberger M; Kovacs MS; Eder A; Nigg A; Schäfer A
Rheumatol Int; 2022 Jun; 42(6):959-966. PubMed ID: 35429290
[TBL] [Abstract][Full Text] [Related]
3. Different humoral but similar cellular responses of patients with autoimmune inflammatory rheumatic diseases under disease-modifying antirheumatic drugs after COVID-19 vaccination.
Andreica I; Blazquez-Navarro A; Sokolar J; Anft M; Kiltz U; Pfaender S; Vidal Blanco E; Westhoff T; Babel N; Stervbo U; Baraliakos X
RMD Open; 2022 Sep; 8(2):. PubMed ID: 36104115
[TBL] [Abstract][Full Text] [Related]
4. Rheumatoid arthritis patients treated with Janus kinase inhibitors show reduced humoral immune responses following BNT162b2 vaccination.
Iancovici L; Khateeb D; Harel O; Peri R; Slobodin G; Hazan Y; Melamed D; Kessel A; Bar-On Y
Rheumatology (Oxford); 2022 Aug; 61(8):3439-3447. PubMed ID: 34849628
[TBL] [Abstract][Full Text] [Related]
5. TNF inhibitors significantly attenuate the humoral immune response to COVID-19 vaccination in patients with rheumatoid arthritis.
Schäfer A; Kovacs MS; Eder A; Nigg A; Feuchtenberger M
Rheumatol Adv Pract; 2023; 7(2):rkad065. PubMed ID: 37560623
[TBL] [Abstract][Full Text] [Related]
6. Kinetics of the B- and T-Cell Immune Responses After 6 Months From SARS-CoV-2 mRNA Vaccination in Patients With Rheumatoid Arthritis.
Farroni C; Picchianti-Diamanti A; Aiello A; Nicastri E; Laganà B; Agrati C; Castilletti C; Meschi S; Colavita F; Cuzzi G; Casetti R; Grassi G; Petrone L; Vanini V; Salmi A; Repele F; Altera AMG; Maffongelli G; Corpolongo A; Salemi S; Di Rosa R; Nalli G; Sesti G; Vaia F; Puro V; Goletti D
Front Immunol; 2022; 13():846753. PubMed ID: 35309297
[TBL] [Abstract][Full Text] [Related]
7. Distinct impact of DMARD combination and monotherapy in immunogenicity of an inactivated SARS-CoV-2 vaccine in rheumatoid arthritis.
Medeiros-Ribeiro AC; Bonfiglioli KR; Domiciano DS; Shimabuco AY; da Silva HC; Saad CGS; Yuki EFN; Pasoto SG; Araujo CSR; Nakai TL; Silva CA; Pedrosa T; Kupa LVK; Silva MSR; Balbi GGM; Kallas EG; Aikawa NE; Bonfa E
Ann Rheum Dis; 2022 May; 81(5):710-719. PubMed ID: 35135832
[TBL] [Abstract][Full Text] [Related]
8. Impact of methotrexate on humoral and cellular immune responses to SARS-CoV-2 mRNA vaccine in patients with rheumatoid arthritis.
Shirata M; Ito I; Tanaka M; Murata K; Murakami K; Ikeda H; Oi I; Hamao N; Nishioka K; Hayashi Y; Nagao M; Hashimoto M; Ito H; Ueno H; Morinobu A; Hirai T
Clin Exp Med; 2023 Dec; 23(8):4707-4720. PubMed ID: 37582911
[TBL] [Abstract][Full Text] [Related]
9. Two-week methotrexate discontinuation in patients with rheumatoid arthritis vaccinated with inactivated SARS-CoV-2 vaccine: a randomised clinical trial.
Araujo CSR; Medeiros-Ribeiro AC; Saad CGS; Bonfiglioli KR; Domiciano DS; Shimabuco AY; Silva MSR; Yuki EFN; Pasoto SG; Pedrosa T; Kupa LVK; Zou G; Pereira RMR; Silva CA; Aikawa NE; Bonfa E
Ann Rheum Dis; 2022 Jun; 81(6):889-897. PubMed ID: 35193873
[TBL] [Abstract][Full Text] [Related]
10. Immune dynamics in SARS-CoV-2 experienced immunosuppressed rheumatoid arthritis or multiple sclerosis patients vaccinated with mRNA-1273.
Verstegen NJM; Hagen RR; van den Dijssel J; Kuijper LH; Kreher C; Ashhurst T; Kummer LYL; Steenhuis M; Duurland M; de Jongh R; de Jong N; van der Schoot CE; Bos AV; Mul E; Kedzierska K; van Dam KPJ; Stalman EW; Boekel L; Wolbink G; Tas SW; Killestein J; van Kempen ZLE; Wieske L; Kuijpers TW; Eftimov F; Rispens T; van Ham SM; Ten Brinke A; van de Sandt CE;
Elife; 2022 Jul; 11():. PubMed ID: 35838348
[TBL] [Abstract][Full Text] [Related]
11. Factors influencing the SARS-CoV-2 infection and vaccination induced immune response in rheumatoid arthritis.
Nemeth D; Vago H; Tothfalusi L; Ulakcsai Z; Becker D; Szabo Z; Rojkovich B; Merkely B; Nagy G
Front Immunol; 2022; 13():960001. PubMed ID: 36311767
[TBL] [Abstract][Full Text] [Related]
12. Reduced humoral response to a third dose (booster) of SARS-CoV-2 mRNA vaccines by concomitant methotrexate therapy in elderly patients with rheumatoid arthritis.
Stahl D; Tho Pesch C; Brück C; Esser RL; Thiele J; Di Cristanziano V; Kofler DM
RMD Open; 2022 Oct; 8(2):. PubMed ID: 36216409
[TBL] [Abstract][Full Text] [Related]
13. An Argentinean cohort of patients with rheumatic and immune-mediated diseases vaccinated for SARS-CoV-2: the SAR-CoVAC Registry-protocol and preliminary data.
Isnardi CA; Schneeberger EE; Kreimer JL; Luna PC; Echeverría C; Roberts K; de la Vega MC; Virasoro BM; Landi M; Quintana R; Exeni MED; Kogan N; Petkovic I; Pereira D; De Los Ángeles Correa M; Zelaya MD; Tissera Y; Elkin MSG; Pisoni CN; Alonso C; Cogo AK; Cosatti MA; García L; Retamozo C; de Los Ángeles Severina M; Nieto RE; Rosemffet M; Mussano E; Bertoli A; Savio VG; Cosentino V; Pons-Estel GJ
Clin Rheumatol; 2022 Oct; 41(10):3199-3209. PubMed ID: 35760939
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness of SARS-CoV-2 vaccination in patients with rheumatoid arthritis (RA) on DMARDs: as determined by antibody and T cell responses.
Saleem B; Ross RL; Bissell LA; Aslam A; Mankia K; Duquenne L; Corsadden D; Carter C; Hughes P; Nadat FA; Mulipa P; Lobb M; Clarke B; Mbara K; Morton R; Dibb S; Chowdhury R; Newton D; Pike A; Kakkar V; Savic S; DelGaldo F; Emery P
RMD Open; 2022 Mar; 8(1):. PubMed ID: 35365569
[TBL] [Abstract][Full Text] [Related]
15. Janus Kinase Inhibitors Improve Disease Activity and Patient-Reported Outcomes in Rheumatoid Arthritis: A Systematic Review and Meta-Analysis of 24,135 Patients.
Tóth L; Juhász MF; Szabó L; Abada A; Kiss F; Hegyi P; Farkas N; Nagy G; Helyes Z
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163173
[TBL] [Abstract][Full Text] [Related]
16. Humoral immune response after different SARS-CoV-2 vaccination regimens.
Rose R; Neumann F; Grobe O; Lorentz T; Fickenscher H; Krumbholz A
BMC Med; 2022 Jan; 20(1):31. PubMed ID: 35057798
[TBL] [Abstract][Full Text] [Related]
17. Comparative Efficacy of JAK Inhibitors for Moderate-To-Severe Rheumatoid Arthritis: A Network Meta-Analysis.
Pope J; Sawant R; Tundia N; Du EX; Qi CZ; Song Y; Tang P; Betts KA
Adv Ther; 2020 May; 37(5):2356-2372. PubMed ID: 32297280
[TBL] [Abstract][Full Text] [Related]
18. A retrospective, longitudinal study of rheumatoid arthritis treatment patterns with Janus kinase inhibitors and other disease-modifying antirheumatic drugs in Japan.
Kaneko Y; Sakurai M; Snijder R; Kokubo S; Kato D
Mod Rheumatol; 2023 Apr; 33(3):448-459. PubMed ID: 35640001
[TBL] [Abstract][Full Text] [Related]
19. Methotrexate reduces vaccine-specific immunoglobulin levels but not numbers of circulating antibody-producing B cells in rheumatoid arthritis after vaccination with a conjugate pneumococcal vaccine.
Kapetanovic MC; Nagel J; Nordström I; Saxne T; Geborek P; Rudin A
Vaccine; 2017 Feb; 35(6):903-908. PubMed ID: 28081972
[TBL] [Abstract][Full Text] [Related]
20. Immunomodulatory drugs have divergent effects on humoral and cellular immune responses to SARS-CoV-2 vaccination in people living with rheumatoid arthritis.
Benoit JM; Breznik JA; Ang JC; Bhakta H; Huynh A; Cowbrough B; Baker B; Heessels L; Lodhi S; Yan E; Ewusie J; Nazy I; Bramson J; Miller MS; Bernatsky S; Larché MJ; Bowdish DME;
Sci Rep; 2023 Dec; 13(1):22846. PubMed ID: 38129594
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
